IOVANCE BIOTHERAPEUTICS INC (IOVA)
Sector: Health Care
2026 Annual Meeting Analysis
IOVANCE BIOTHERAPEUTICS INC · Meeting: June 10, 2026
Directors FOR
0
Directors AGAINST
6
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Dr. Dukes has served as Chairman since 2016, and under his oversight the stock has lost roughly 41% over three years while the company's own compensation peer group gained about 58% on average — a gap of approximately 99 percentage points, far exceeding the 20-point trigger for companies with negative absolute returns; the five-year record offers no relief, with IOVA down 89% versus peers down only 26%, so the longer-term track record confirms sustained underperformance rather than a temporary dip.
Dr. Countouriotis has served since 2019, giving her full overlap with the three-year underperformance period; the stock's roughly 99-percentage-point shortfall versus peers triggers a vote against under the policy, and the five-year record confirms the pattern of sustained underperformance, so no mitigant applies.
Mr. Maynard has been a director since 2015 and has full overlap with the underperformance period; the roughly 99-percentage-point gap versus the company's own peer group far exceeds the 20-point trigger, and the five-year record similarly shows no relief from the sustained underperformance.
Mr. Rothbaum has served since 2016 and is the company's largest shareholder and a compensation committee member with full overlap over the underperformance period; the stock has trailed the company's peer group by roughly 99 percentage points over three years, well above the 20-point trigger, and the five-year picture shows the same pattern of sustained underperformance with no mitigant available.
Dr. Vogt joined the board in 2024 but has served as Interim CEO since June 2021, giving him executive-level responsibility throughout the underperformance period; as an executive director he is subject to the same TSR trigger as all other directors, the three-year gap of roughly 99 percentage points versus peers far exceeds the threshold, and the five-year record provides no mitigant — his board tenure of just under 24 months is noted as partial mitigation but does not exempt him given his executive role over the full period.
Dr. Weiser has served since 2018 and chairs the compensation committee, giving him full overlap with the underperformance period; the stock has trailed the company's peer group by roughly 99 percentage points over three years — far above the 20-point trigger — and the five-year record of underperformance confirms this is not a short-term dip.
For Analysis
All six director nominees trigger a vote against under the TSR underperformance policy. IOVA's stock has declined roughly 41% over three years while its own disclosed compensation peer group gained approximately 58% on average, a gap of about 99 percentage points — far exceeding the 20-point threshold that applies when absolute three-year returns are negative. The five-year record (IOVA down 89% versus peers down 26%, a gap of roughly 63 percentage points) confirms sustained underperformance across the full board tenure of all nominees, so the five-year mitigant does not apply to any director. The policy requires a vote against each qualifying director individually, and all six nominees have meaningful tenure overlap with the underperformance period.
Say on Pay
✓ FORCEO
Frederick G. Vogt, Ph.D., J.D.
Total Comp
$1,888,175
Prior Support
N/A
The CEO's total reported compensation of approximately $1.9 million is modest for a company of IOVA's market cap and role complexity, and the pay mix includes meaningful variable components tied to annual performance objectives and equity awards. While the company's stock has significantly underperformed the XBI — SPDR S&P Biotech ETF and the company's own peer group over the past three years, the CEO's actual compensation level is low enough that it does not trigger the pay-level or pay-for-performance thresholds under the policy; the compensation structure also includes no guaranteed bonuses, no excessive perquisites, and a functioning clawback framework consistent with Dodd-Frank requirements.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$3,242,740
Non-Audit Fees
$0
Ernst & Young LLP charged only audit fees of approximately $3.2 million in 2025 with zero non-audit, tax, or other fees, meaning the non-audit fee ratio is 0% — well below the 50% threshold that would raise independence concerns; EY is a Big 4 firm appropriate for a company of IOVA's size and complexity, and auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire under policy.
Overall Assessment
The most significant issue at this annual meeting is severe and sustained stock underperformance: IOVA's shares have declined roughly 41% over three years while its own disclosed peer group gained approximately 58%, a gap of about 99 percentage points that triggers a vote against all six director nominees under the TSR underperformance policy. The Say on Pay vote passes muster because the CEO's total pay of approximately $1.9 million is modest relative to the role and the pay structure is genuinely variable, while the auditor ratification is straightforward with zero non-audit fees and a Big 4 firm in place.
Compensation Peer Group
38 companies disclosed in 2026 proxy filing